154 related articles for article (PubMed ID: 29650886)
1. [Usefulness of Suvorexant for Complicated Delirium in Cancer Patients Who Experience Sleep Disturbance during Hospitalization].
Kessoku T; Kusakabe A; Matsuura T; Honda Y; Yoshimi A; Goto A; Yoshida H; Sukegawa A; Hata C; Saito Y; Miyashita Y; Yashiro R; Komori T; Arai S; Nakajima A; Ichikawa Y
Gan To Kagaku Ryoho; 2018 Mar; 45(Suppl 1):92-94. PubMed ID: 29650886
[TBL] [Abstract][Full Text] [Related]
2. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Hatta K; Kishi Y; Wada K; Takeuchi T; Hashimoto N; Suda K; Taira T; Tsuchida K; Ohmori T; Akizuki N; Nishio Y; Nakanishi Y; Usui C; Kurata A; Horikawa N; Eguchi H; Ito S; Muto H; Nakamura H; Uchimura N
J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851436
[TBL] [Abstract][Full Text] [Related]
4. Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.
Henmi R; Nakamura T; Mashimoto M; Takase F; Ozone M
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):369-377. PubMed ID: 38820374
[TBL] [Abstract][Full Text] [Related]
5. Suvorexant for the prevention of delirium: A meta-analysis.
Xu S; Cui Y; Shen J; Wang P
Medicine (Baltimore); 2020 Jul; 99(30):e21043. PubMed ID: 32791676
[TBL] [Abstract][Full Text] [Related]
6. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK
Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
8. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
9. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H
J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183
[TBL] [Abstract][Full Text] [Related]
10. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
11. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
[TBL] [Abstract][Full Text] [Related]
13. Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial.
Hatta K; Kishi Y; Wada K; Takeuchi T; Ito S; Kurata A; Murakami K; Sugita M; Usui C; Nakamura H;
J Clin Psychiatry; 2017; 78(8):e970-e979. PubMed ID: 28767209
[TBL] [Abstract][Full Text] [Related]
14. Melatonin, Ramelteon, Suvorexant, and Dexmedetomidine to Promote Sleep and Prevent Delirium in Critically Ill Patients: A Narrative Review With Practical Applications.
Fontaine GV; Der Nigoghossian C; Hamilton LA
Crit Care Nurs Q; 2020; 43(2):232-250. PubMed ID: 32084065
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant for Adults with Insomnia.
Scarff JR
J S C Med Assoc; 2015; 111(1):28-9. PubMed ID: 27124984
[No Abstract] [Full Text] [Related]
16. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
[TBL] [Abstract][Full Text] [Related]
17. Suvorexant (Belsomra) for insomnia.
Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
[No Abstract] [Full Text] [Related]
18. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study.
Okino K; Yamada H; Tomioka H; Nozaki S; Iwanami A; Inamoto A
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):589-593. PubMed ID: 34411006
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
20. Suvorexant approved for insomnia.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(18):1524. PubMed ID: 25174007
[No Abstract] [Full Text] [Related]
[Next] [New Search]